PERSEPHONE - SANOFi EFC18243 A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants.
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Sanofi US Services, Inc.
Start Date
February 6, 2026
End Date
September 17, 2030
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Sanofi US Services, Inc.
Start Date
February 6, 2026
End Date
September 17, 2030